Novus Biologicals

Editor's Note: This is the second of a two-part series. Read Frank Mortari's comments on M&A possibilities. Bio-Techne (NASDAQ: TECH) has made two major acquisitions since June, spending $60 million to acquire Novus Biologicals and $300 million to pick up ProteinSimple. For a small...

Bio-Techne (NASDAQ: TECH) announced the $60 million acquisition of Novus Biologicals earlier this month and the $300 million acquisition of ProteinSimple in June.   In an exclusive interview with Benzinga, Director of Business Development Frank Mortari discussed M&A activity in the...